Atrial fibrillation

the options with their healthcare professional at least once a year. Healthcare professionals discuss the options at least once a year with adults with atrial fibrillation who are prescribed anticoagulation. There should not be mandatory use of vitamin K antagonists before offering non-vitamin K antagonist oral anticoagulants for people with non-valvular atrial fibrillation. Commissioners specify that primary and secondary care service providers have protocols in place to ensure that adults with atrial fibrillation who are prescribed anticoagulation can discuss the options with their healthcare professional at least once a year. Adults with atrial fibrillation who are prescribed an anticoagulant have the chance to talk with their doctor at least once a year about the types of anticoagulant they could have and the advantages and disadvantages of each. Source guidance Atrial fibrillation: diagnosis and management. NICE guideline 196 (2021), recommendations 1.4.1, 1.6.1 and 1.6.3 to 1.6.5 Definitions of terms used in this quality statement Anticoagulants Anticoagulants for people with atrial fibrillation include direct-acting oral anticoagulants (such as apixaban, dabigatran, edoxaban and rivaroxaban) and vitamin K antagonists. [Adapted from NICE's guideline on atrial fibrillation, recommendations 1.6.3 to 1.6.5] Discuss Any discussion with an adult with atrial fibrillation should involve both oral and
